IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) - Документы SEC, Годовой отчет, Доверенное заявление

Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 D

Exhibit 99.1 Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Phase 1 single ascending dose HBV data for IMC-I109V will be presented

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Immunocore Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39992 Immunocore Holdings p

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation) (

As filed with the Securities and Exchange Commission on May 7, 2025

As filed with the Securities and Exchange Commission on May 7, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39992 Immunocore Holdings

Calculation of Filing Fee Tables Form S-8 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value £0.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation) (C

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 202

Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure cand

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ☐ U.S. BANK TRUST

Exhibit 25.2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ☐ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E

As filed with the Securities and Exchange Commission on March 17, 2025

As filed with the Securities and Exchange Commission on March 17, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Immunocore Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation)

Calculation of Filing Fee Table Form S-3 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value GBP 0.

First Supplemental Indenture, dated as of March 17, 2025, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee.

Exhibit 4.10 IMMUNOCORE HOLDINGS PLC AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of March 17, 2025 2.50% Convertible Senior Notes due 2030 FIRST SUPPLEMENTAL INDENTURE, dated as of March 17, 2025 (this “Supplemental Indenture”), among Immunocore Holdings plc, a public limited company incorporated under the laws of England and Wales (the “Compa

IMMUNOCORE HOLDINGS PLC U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of March 17, 2025 2.50% Convertible Senior Notes due 2030

Exhibit 4.1 IMMUNOCORE HOLDINGS PLC AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of March 17, 2025 2.50% Convertible Senior Notes due 2030 FIRST SUPPLEMENTAL INDENTURE, dated as of March 17, 2025 (this “Supplemental Indenture”), among Immunocore Holdings plc, a public limited company incorporated under the laws of England and Wales (the “Compan

Up to $150,000,000 of 2.50% Convertible Senior Notes due 2030 Up to 1,584,014 American Depositary Shares (representing 1,584,014 ordinary shares) issuable upon conversion of the notes

TABLE OF CONTENTS Filed pursuant to Rule 424(b)(7) Registration No. 333-278120 Prospectus Supplement (To prospectus dated March 21, 2024) Up to $150,000,000 of 2.50% Convertible Senior Notes due 2030   Up to 1,584,014 American Depositary Shares (representing 1,584,014 ordinary shares) issuable upon conversion of the notes   On February 2, 2024, we issued and sold $402.5 million aggregate principal

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation)

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, an

Exhibit 99.1 Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH Enrollment in MAD portion of the trial continues with h

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK

Exhibit 99.1 Immunocore reports fourth quarter and full year 2024 financial results and provides a business update KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first pati

Form of Restricted Share Unit Agreement under 2021 Equity Incentive Plan

Exhibit 10.17 IMMUNOCORE HOLDINGS PLC 2021 EQUITY INCENTIVE PLAN WITH NON-EMPLOYEE SUB-PLAN RESTRICTED SHARE UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Share Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2021 Equity Incentive Plan with Non-Employee Sub-Plan (as amended from time to time, the “Plan”) of Immunocore Holdings Plc (th

Employment Agreement between the Registrant and

Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into by and between Travis Coy (“Executive”) and Immunocore, LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of Immunocore Holdings plc (“Parent”), a company incorporated under the laws of England and Wales (hereinafter referred to together as the “Company”) and is effective a

and Window Period

Exhibit 19.1 Immunocore Holdings plc Amended and Restated Insider Trading and Window Period Policy Introduction During the course of your relationship with Immunocore Holdings plc (the “Company”), you may receive material information that is not yet publicly available (“inside information” or “material nonpublic information”) about the Company or other publicly traded companies with which the Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission File Number 001-39992 Immunoco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Immunocore Hold

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporati

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Registrant are as follows: Name Jurisdiction of incorporation Immunocore Limited England and Wales Immunocore LLC Delaware, United States Immunocore Commercial LLC Delaware, United States Immunocore Ireland Limited Ireland Immunocore GmbH Switzerland Immunocore Nominees Limited England and Wales

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3

Exhibit 99.1 Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential data readouts beginning with TEBE-AM in 2026 Enrolling Phase 1/2 trial with bren

Transformative immunomodulating medicines for patients January 2025 1 2 Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Ac

Exhibit 99.2 Transformative immunomodulating medicines for patients January 2025 1 2 Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “estimate” and similar expressions (as well as other w

1 Platinum refractory or resistant serous ovarian carcinoma. 2 NSCLC = Non-small cell lung cancer 3 Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commer

Exhibit 99.3 1 Platinum refractory or resistant serous ovarian carcinoma. 2 NSCLC = Non-small cell lung cancer 3 Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world. 4 Program is not HLA restricted (i.e. universal for all populations). 5 Submission Leading bis

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 Immunocore Hold

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporati

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Exhibit 99.1 Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomo

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) / RTW INVESTMENTS, LP - IMMUNOCORE HOLDINGS PLC Passive Investment

SC 13G/A 1 p24-3267sc13ga.htm IMMUNOCORE HOLDINGS PLC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value of £0.002 per share (Title of Class of Securities) 45258D105** (CUSIP Number) September 30, 2024 (Date of event which requires filing of thi

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) / Rock Springs Capital Management LP Passive Investment

SC 13G/A 1 rocksprings-imcr093024a4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Immunocore Holdings plc (Name of Issuer) Ordinary Share, nominal value £0.002 per share (Title of Class of Securities) 45258D105** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stat

JOINT FILING AGREEMENT

EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Immunocore Holdings plc is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Immunocore Holdings plc (Name of Issuer) Common Stock (Title of Class of Securities) 45258D105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39992 Immunocore Holdi

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM);

Exhibit 99.1 Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resis

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporatio

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pre-treated, platinum-resistant ova

Exhibit 99.1 Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pre-treated, platinum-resistant ovarian cancer patients T cell fitness gene expression signature in blood is an important parameter of clinical activity for tebentafusp in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2024 Immunocore Hol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporat

Immunocore announces transition of Chief Financial Officer

Exhibit 99.1 Immunocore announces transition of Chief Financial Officer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 29 August 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectiou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 Immunocore Holdin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39992 Immunocore Holdings p

Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cuta

Exhibit 99.1 Immunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma ongoing, following conversion of Phase 2/3 trial – expect to complete enrollment in 1H 2026 Registrational Phase 3 (PRISM-

Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 31.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Brian Di Donato, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Immunocore Holdings plc; 2.Based on my knowledge, this report does not contain any untrue statement of a material

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Immunocore Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation)

Articles of Association of Immunocore Holdings plc

immunocore-amendedarticl 11022380 v3 COOLEY (UK) LLP, 22 BISHOPSGATE, LONDON EC2N 4BQ, UK T: +44 (0) 20 7583 4055 F: +44 (0) 20 7785 9355 WWW.

Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 31.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bahija Jallal, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Immunocore Holdings plc; 2.Based on my knowledge, this report does not contain any untrue statement of a material f

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation) (

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy brenetafusp (IMC-F106C) in late-line cutaneous melanoma de

Exhibit 99.1 Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy brenetafusp (IMC-F106C) in late-line cutaneous melanoma demonstrated promising disease control (partial response and stable disease), progression free survival (PFS), and ctDNA molecular response

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation) (

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA, all patients randomized from start of TEBE-AM Phase

Exhibit 99.1 Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA, all patients randomized from start of TEBE-AM Phase 2/3 trial will be included in the Phase 3 intent-to-treat population Phase 3 will continue three arms: KIMMTRAK monotherapy, KIMMTRAK in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Immunocore Holdings

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation) (

[Signatures Appear on Following Page]

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT IMMUNOCORE TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO SIDE LETTER This AMENDMENT NO. 1 TO SIDE LETTER (the “Amendment”) dated as of February 6, 2024, is made with reference to the Letter Agreement dated January 21, 2021

Registration Rights Agreement, dated May 28, 2024, by and among the Company and 667, L.P. and Baker Brothers Life Sciences, L.P.

Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of May 28, 2024 by and between Immunocore Holdings plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation) (

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenet

Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39992 Immunocore Holdings

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation) (C

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

1,220,063 American Depositary Shares (Representing 1,220,063 Ordinary Shares)

TABLE OF CONTENTS Filed pursuant to Rule 424(b)(7) Registration No. 333-278120 Prospectus Supplement (To prospectus dated March 21, 2024) 1,220,063 American Depositary Shares (Representing 1,220,063 Ordinary Shares)   The selling shareholders referred to in this prospectus supplement may offer and resell up to 1,220,063 of our American Depositary Shares, or ADSs, pursuant to this prospectus supple

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation)

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

As filed with the Securities and Exchange Commission on March 21, 2024

As filed with the Securities and Exchange Commission on March 21, 2024 Registration No.

As filed with the Securities and Exchange Commission on March 21, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 21, 2024 Registration No.

Cooley LLP 500 Boylston Street 14th Floor Boston, MA 02116-3736 t: +1 617 937 2300 f: +1 617 937 2400 cooley.com

Exhibit 5.3 Courtney Thorne T: +1 617 937 2318 [email protected] March 20, 2024 Immunocore Holdings plc 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom Ladies and Gentlemen: We have acted as special U.S. counsel to Immunocore Holdings plc, a public limited company incorporated under the laws of England and Wales (the “Company”), in connection with the filing by the Company

Calculation of Filing Fee Tables Form S-3ASR

Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value £0.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value £0.

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) / GENERAL ATLANTIC LLC - AMENDMENT NO. 6 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value £0.002 (Title of Class of Securities) 45258D105** (CUSIP Number) Michael Gosk c/o General Atlantic Service Company, L.P. 55 East 52nd Street, 33rd Floor New York, New York 10055 (212

Employment Agreement between the Registrant and David Berman, MD., Ph.D., dated January 29, 2021

Exhibit 10.13 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between David Berman (“Executive”) and Immunocore, LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of Immunocore Holdings Limited, a company incorporated under the laws of England and Wales to be renamed as Immunocore Hold

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission File Number 001-39992 Immunocore Holdings plc (E

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Registrant are as follows: Name Jurisdiction of incorporation Immunocore Limited England and Wales Immunocore LLC United States Immunocore Commercial LLC United States Immunocore Ireland Limited Ireland Immunocore GmbH Switzerland Immunocore Nominees Limited England and Wales

Transformative immunomodulating medicines for patients 4Q 2023 & FY 2023 Financial Results & Business Update This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation

Exhibit 99.2 Transformative immunomodulating medicines for patients 4Q 2023 & FY 2023 Financial Results & Business Update This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate” and similar expressions (as well as other wor

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial access to KIMMTRAK globally, and p

Exhibit 99.1 Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial access to KIMMTRAK globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma Clinical tr

Immunocore Holdings plc Incentive Compensation Recoupment Policy

Exhibit 97.1 Immunocore Holdings plc Incentive Compensation Recoupment Policy Approved and Adopted on 26 October 2023 1. Introduction The Remuneration Committee (the “Remuneration Committee”) of the Board of Directors (the “Board”) of Immunocore Holdings plc, a public limited company incorporated under the laws of England and Wales (the “Company”), has determined that it is in the best interests o

Employment Agreement between the Registrant and Brian Di Donato, dated January 29, 2021

Exhibit 10.12 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Brian Di Donato (“Executive”) and Immunocore, LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of Immunocore Holdings Limited, a company incorporated under the laws of England and Wales to be renamed as Immunocore H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Immunocore Hold

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporati

Employment Agreement between the Registrant and Tina St Leger, dated August 2, 2021

Exhibit 10.14 IMMUNOCORE IMMUNOCORE Contract of Employment Tina St Leger Dated 2 August 2021 IMMUNOCORE AMENDED AND RESTATED CONTRACT OF EMPLOYMENT 1. PARTIES 1.1 This employment agreement is made between Tina St Leger, [***], “you” and your employer, Immunocore Limited (company number 06456207), 101 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY (hereinafter called “THE COMPANY”) and is

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) / RTW INVESTMENTS, LP - RTW INVESTMENTS, LP Passive Investment

SC 13G/A 1 p24-0435sc13ga.htm RTW INVESTMENTS, LP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value of £0.002 per share (Title of Class of Securities) 45258D105** (CUSIP Number) December 31, 2023 (Date of event which requires filing of this sta

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) / Rock Springs Capital Management LP Passive Investment

SC 13G/A 1 rocksprings-imcr123123a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Immunocore Holdings plc (Name of Issuer) Ordinary Share, nominal value £0.002 per share (Title of Class of Securities) 45258D105** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this State

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immunocore Holdings PLC (Name of Issuer) Common Stock (Title of Class of Securities) 45258D105 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Immunocore Holdings PLC (Name of Issuer) Common Stock (Title of Class of Securities) 45258D105 (CUSIP Number) January 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

Immunocore Prices Upsized Convertible Senior Notes Offering

Exhibit 99.1 Immunocore Prices Upsized Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 30, 2024) Immunocore Holdings plc (Nasdaq: IMCR) today announced the pricing of $350.0 million aggregate principal amount of 2.50% convertible senior notes due 2030 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A u

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporatio

Form of Global Note, representing the Company’s 2.50% Convertible Senior Notes due 2030 (included as Exhibit A to the Indenture filed as Exhibit 4.1).

Exhibit 4.1 IMMUNOCORE HOLDINGS PLC AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of February 2, 2024 2.50% Convertible Senior Notes due 2030 TABLE OF CONTENTS Page ARTICLE 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 14 Section 1.03. References to Conversion 14 ARTICLE 2 Issue, Description, Execution, Registration and Exchange o

IMCR / Immunocore Holdings plc - Depositary Receipt (Common Stock) / BAKER BROS. ADVISORS LP - SC13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No.

In the confidential preliminary offering memorandum to be used in connection with a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended, by

Exhibit 99.2 In the confidential preliminary offering memorandum to be used in connection with a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended, by Immunocore Holdings plc, the Company provided the following overview of the Company’s business as updates or supplements to the information provided

Immunocore Announces Proposed Convertible Senior Notes Offering

Exhibit 99.1 Immunocore Announces Proposed Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 29, 2024) Immunocore Holdings plc (Nasdaq: IMCR), today announced its intention to offer, subject to market and other conditions, $300.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to qualif

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporatio

5 1 Platinum refractory or resistant serous ovarian carcinoma.; 2. Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the develop

Exhibit 99.3 5 1 Platinum refractory or resistant serous ovarian carcinoma.; 2. Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world.; 3. Program is not HLA restricted (ie. universal for all populations) Leading bispecific TCR pipeline Oncology Infectious Autoi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Immunocore Holdin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation

Transformative immunomodulating medicines for patients January 2024 This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”,

Exhibit 99.2 Transformative immunomodulating medicines for patients January 2024 This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate” and similar expressions (as well as other words or expressions referencing future even

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn) globally, and pursuing future growth opportunities with t

Exhibit 99.1 Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn) globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma Multiple clinical readouts expected to start in 2Q 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Immunocore Holdin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Immunocore Holdings plc (Exact name of registrant as specified in its Charter) England and Wales 001-39992 Not Applicable (State or other jurisdiction of incorporation

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major markets with continued reimbursement expansion globally New P

Exhibit 99.3 Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major markets with continued reimbursement expansion globally New Phase 3 clinical trial of KIMMTRAK adjuvant therapy for uveal (or ocular) melanoma (ATOM) in collaboration with the European Organisation

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated interim financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K, or this Report, sub

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (

Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements

Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements Unaudited Condensed Consolidated Statements of Profit / (Loss) and Comprehensive (Loss) / Income Three Months Ended September 30, Nine Months Ended September 30, Notes 2023 £’000 2022 £’000 2023 £’000 2022 £’000 Product revenue, net 3 49,719 33,252 137,285 64,926 Pre-product revenue, net 3 — 3,051 —

IMCR / Immunocore Holdings plc - ADR / GENERAL ATLANTIC LLC - AMENDMENT NO. 5 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value £0.002 (Title of Class of Securities) 45258D105** (CUSIP Number) Michael Gosk c/o General Atlantic Service Company, L.P. 55 East 52nd Street, 33rd Floor New York, New York 10055 (212

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-399

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Ad

Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements

Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss Three months ended June 30, Six Months Ended June 30, Notes 2023 £’000 2022 £’000 2023 £’000 2022 £’000 Product revenue, net 3 45,514 23,992 87,566 31,674 Pre-product revenue, net 3 — 3,708 — 6,537 Total revenue from sale of t

2Q 2023 Financial Results & Business Update Thursday, August 10, 2023 Forward Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Ac

Exhibit 99.4 2Q 2023 Financial Results & Business Update Thursday, August 10, 2023 Forward Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate” and similar expressions (as well as other words or expr

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated interim financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K, or this Report, sub

Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by

Exhibit 99.3 Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by year-end New Phase 3 Trial for IMC-F106C (PRAME-A02) in first-line cutaneous melanoma (PRISM-MEL301); expect first patient randomized by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-39992

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Addr

IMCR / Immunocore Holdings plc - ADR / GENERAL ATLANTIC LLC - AMENDMENT NO. 4 Activist Investment

SC 13D/A 1 eh23037027513da4-imcr.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value £0.002 (Title of Class of Securities) 45258D105** (CUSIP Number) Michael Gosk c/o General Atlantic Service Company, L.P. 55 East

Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival

Exhibit 99.1 Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3 June 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the develop

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-39992

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Addr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39992

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Addre

Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £42.1 million ($52.0 million) in Q1 2023, with continued commercial expansion Randomization started in Phase 2/3 trial with KIMMTRAK in prev

Exhibit 99.3 Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £42.1 million ($52.0 million) in Q1 2023, with continued commercial expansion Randomization started in Phase 2/3 trial with KIMMTRAK in previously-treated, advanced melanoma Patients continue to enroll in monotherapy and combination arms of IMC-F106C (PRAME-HLA-A02) Phase 1/2

Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements

Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income Three months ended March 31, Notes 2023 £’000 2022 £’000 Product revenue, net 3 42,052 7,682 Pre-product revenue, net 3 — 2,829 Total revenue from sales of therapies 42,052 10,511 Collaboration revenue 3 2,489 11,963 T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39992

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Addre

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated interim financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K, or this Report, sub

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-3999

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Add

Immunocore Holdings plc (incorporated and registered in England and Wales under the Companies Act 2006 with registered number 13119746) Notice of Annual General Meeting 2023 to be held at the offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N 4B

Exhibit 99.1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant, or other independent professional adviser. If you have recently sold or transferred all of your shares in Immunocore Holdings plc, you should fo

Time Sensitive

Exhibit 99.3 Time Sensitive Materials Depositary’s Notice of Annual General Meeting of Shareholders of Immunocore Holdings plc ADSs: American Depositary Shares. ADS CUSIP No.: 45258D105. RADS CUSIP No.: 4525D998. ADS Record Date: April 10, 2023. Meeting Specifics: Annual General Meeting of Shareholders to be held on Tuesday, May 16, 2023 at 2:00 P.M. (British Summer Time) at the offices of Cooley

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-3999

6-K 1 brhc200515386k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire

To be effective, all proxy appointments must be lodged with the Company’s Registrars at: Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol BS99 6ZY by 12 May 2023 at 2.00 pm BST

Exhibit 99.2 All Correspondence to: Computershare Investor Services PLC The Pavilions, Bridgwater Road, Bristol, BS99 6ZY Form of Proxy - Annual General Meeting to be held on 16 May 2023 at 2.00 pm BST Cast your Proxy online...It's fast, easy and secure! www.investorcentre.co.uk/eproxy Control Number: 918356 SRN: PIN: You will be asked to enter the Control Number, Shareholder Reference Number (SRN

Annual General Meeting of Shareholders The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on May 10, 2023 for action to be taken.

Exhibit 99.4 Annual General Meeting of Shareholders The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on May 10, 2023 for action to be taken. 2023 VOTING INSTRUCTIONS AMERICAN DEPOSITARY SHARES Immunocore Holdings plc (the “Company”) ADS CUSIP No.: 45258D105. RADS CUSIP No.: 4525D998. ADS Record Date: April 10, 2023. Me

In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated with longer overall survival (OS) Median 46 months follow up from Phase 2 trial confirms median OS of 16.8 months, with landmark OS rates approximately double historical

Exhibit 99.1 Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated with longer overall survival (OS) Median 46 months follow up from Phase 2 trial confirms median OS of 16.8 months, with landmark OS rates approximately double historical rates in metastat

Calculation of Filing Fee Tables Form S-8 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value $0.

As filed with the Securities and Exchange Commission on April 6, 2023

S-8 1 brhc10050696s8.htm S-8 As filed with the Securities and Exchange Commission on April 6, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Immunocore Holdings plc (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or other jurisdiction o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-3999

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Add

FORWARD LOOKING STATEMENTS This letter contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “can,” “will,” “believe,” “expect,” “plan,” “a

Exhibit 99.1 FORWARD LOOKING STATEMENTS This letter contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “can,” “will,” “believe,” “expect,” “plan,” “anticipate,” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to id

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-3999

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Add

Letter from KPMG LLP, dated March 1, 2023

Exhibit 16.1 March 1, 2023 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We are currently principal accountants for Immunocore Holdings plc and, under the date of March 1, 2023 we reported on the consolidated financial statements of Immunocore Holdings plc as of and for the years ended December 31, 2022 and 2021, and the effectiveness of internal control over fina

Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F of Immunocore Holdings plc (the “Company”) for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-3999

6-K 1 brhc100490146k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Brian Di Donato, certify that: 1. I have reviewed this annual report on Form 20-F of Immunocore Holdings plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statemen

Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bahija Jallal, certify that: 1. I have reviewed this annual report on Form 20-F of Immunocore Holdings plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement

Immunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of £42 million ($51 million) in Q4 2022 and £117 million ($141 million) in 2022; approved in over 30 countries and nearly 200 patients on globa

Exhibit 99.1 Immunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of £42 million ($51 million) in Q4 2022 and £117 million ($141 million) in 2022; approved in over 30 countries and nearly 200 patients on global early access program Enrolling IMC-F106C (PRAME-HLA-A02) in monotherapy and combination arms of Phase 1/2 clinical trial and expanding

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (Nos. 333-255182 and 333-265000) on Form S-8 and registration statement (No. 333-264105) on Form F-3 of our reports dated March 1, 2023, with respect to the consolidated financial statements of Immunocore Holdings plc and the effectiveness of internal co

Enables productive cytotoxic T cell interface* Potent killing of HIV infected CD4 T cells IMC-M113V redirects T cells to eliminate HIV-infected cells in vitro * Research tool version of IMC-M113V 38 -14 -10 -9 25 0 50 75 100 -13 -12 -11 log [IMC-M113

Exhibit 99.2 Enables productive cytotoxic T cell interface* Potent killing of HIV infected CD4 T cells IMC-M113V redirects T cells to eliminate HIV-infected cells in vitro * Research tool version of IMC-M113V 38 -14 -10 -9 25 0 50 75 100 -13 -12 -11 log [IMC-M113V], M Targets: C8166 A2B2M cells (HLA-A2hi) + HIV Effectors: CD8+ T cells from HIV-naïve donors % elimination of HIV infected cells EC50

Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV Data from the single ascending dose part of the Phase 1 trial shows IMC-M113V is well tolerated Expected markers o

Exhibit 99.1 Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV Data from the single ascending dose part of the Phase 1 trial shows IMC-M113V is well tolerated Expected markers of T cell activation observed in half of participants at 15-mcg dose; plasma viral load remained suppressed throughout dosing and follow-u

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (

IMCR / Immunocore Holdings plc / RTW INVESTMENTS, LP - IMMUNOCORE HOLDINGS PLC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value of £0.002 per share (Title of Class of Securities) 45258D105** (CUSIP Number) October 31, 2022 and December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate bo

IMCR / Immunocore Holdings plc / Rock Springs Capital Management LP Passive Investment

SC 13G/A 1 rocksprings-imcr123122a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immunocore Holdings plc (Name of Issuer) Ordinary Share, nominal value £0.002 per share (Title of Class of Securities) 45258D105** (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this State

IMCR / Immunocore Holdings plc / GENERAL ATLANTIC LLC - AMENDMENT NO. 3 Activist Investment

SC 13D/A 1 eh23032132613da3-imcr.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value £0.002 (Title of Class of Securities) 45258D105** (CUSIP Number) Michael Gosk c/o General Atlantic Service Company, L.P. 55 East

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (A

Transformative Medicines for Patients Bahija Jallal, PhD – Chief Executive Officer 41st Annual J.P. Morgan Healthcare Conference JANUARY 11TH, 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Lit

Exhibit 99.1 Transformative Medicines for Patients Bahija Jallal, PhD – Chief Executive Officer 41st Annual J.P. Morgan Healthcare Conference JANUARY 11TH, 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “can,” “will,” “believe,” “expect,” “plan,” “anticipate”, “potential” and similar expres

Immunocore announces strategic priorities including pipeline expansion for 2023 -2024 KIMMTRAK (tebentafusp-tebn) approved in over 30 countries with continued global expansion in 2023-2024; preliminary unaudited net sales of ~$50 million in Q4 and ~$

EX-99.1 2 brhc10046437ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immunocore announces strategic priorities including pipeline expansion for 2023 -2024 KIMMTRAK (tebentafusp-tebn) approved in over 30 countries with continued global expansion in 2023-2024; preliminary unaudited net sales of ~$50 million in Q4 and ~$140 million for full year 2022 Priority for IMC-F106C (PRAME HLA-A02) is enrollment in mono

Transformative Medicines for Patients January 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “can,” “will,” “believe,” “expect,” “plan,” “ant

Exhibit 99.2 Transformative Medicines for Patients January 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “can,” “will,” “believe,” “expect,” “plan,” “anticipate,” “potential” and similar expressions (as well as other words or expressions referencing future events or circumstances) are inte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39

6-K 1 brhc100464376k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshi

1 Multiple candidates in oncology and infectious diseases Delivering leading bispecific TCR pipeline Candidate Target Indication IND-enabling Phase 1 Phase 2 Phase 3 Approved gp100 Uveal melanoma Tebentafusp Advanced melanoma IMC-F106C PRAME-A02 Mult

Exhibit 99.3 1 Multiple candidates in oncology and infectious diseases Delivering leading bispecific TCR pipeline Candidate Target Indication IND-enabling Phase 1 Phase 2 Phase 3 Approved gp100 Uveal melanoma Tebentafusp Advanced melanoma IMC-F106C PRAME-A02 Multiple solid tumors Multiple solid tumors 2L+ cutaneous melanoma PRR Ovarian* Advanced endometrial 2L+ NSCLC IMC-P115C PRAME-A02-HLE Multip

IMCR / Immunocore Holdings plc / GENERAL ATLANTIC LLC - AMENDMENT NO. 2 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value £0.002 (Title of Class of Securities) 45258D105** (CUSIP Number) Michael Gosk c/o General Atlantic Service Company, L.P. 55 East 52nd Street, 33rd Floor New York, New York 10055 (212

IMCR / Immunocore Holdings plc / GENERAL ATLANTIC LLC - AMENDMENT NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value £0.002 (Title of Class of Securities) 45258D105** (CUSIP Number) Michael Gosk c/o General Atlantic Service Company, L.P. 55 East 52nd Street, 33rd Floor New York, New York 10055 (212

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (

Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4 expression IMC-C103C has a manageable safety profile

Exhibit 99.1 Immunocore presents ovarian cancer expansion data for ImmTAC? candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4 expression IMC-C103C has a manageable safety profile and demonstrated signals of clinical activity The RECIST response rate was low in the population with zero or very low MAGE-A4 expressio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (

Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer potential to address large number of patients without HLA restrictions Agreement combines Gadeta’s gamma delta target and TC

EX-99.1 2 brhc10045015ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer potential to address large number of patients without HLA restrictions Agreement combines Gadeta’s gamma delta target and TCR identification expertise with Immunocore’s TCR bispecific engineering, development and co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4R

INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Profit / Loss and Other Comprehensive Loss for the Three and Nine Months Ended September 30, 2022 and 2021 2 Unaudited Condensed Consolidated Statements of Financial Position as at September 30, 2022 and December 31, 2021 3 Unaudited Condensed Consolidated Stateme

Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is unchanged relative to baseline in biopsies at time of tumo

Exhibit 99.1 Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is unchanged relative to baseline in biopsies at time of tumor progression Patients with radiographic progression who retain expression of the antigen processing machinery have long survival (OXFORD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (

Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity data for IMC-F106C, the first off-the-shelf TCR therapy t

EX-99.3 4 brhc10043858ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 PRESS RELEASE Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity data for IMC-F106C, the first off-the-shelf TCR therapy targeting PRAME, presented at ESMO 2022 Cash and cash equivalents of £347 mill

LOAN AGREEMENT Dated as of November 8, 2022 IMMUNOCORE LIMITED (as Borrower, and a Credit Party), IMMUNOCORE HOLDINGS PLC (as Parent, and a Credit Party), IMMUNOCORE LLC IMMUNOCORE COMMERCIAL LLC IMMUNOCORE IRELAND LIMITED (as additional Credit Parti

Exhibit 99.4 Execution Version LOAN AGREEMENT Dated as of November 8, 2022 among IMMUNOCORE LIMITED (as Borrower, and a Credit Party), IMMUNOCORE HOLDINGS PLC (as Parent, and a Credit Party), IMMUNOCORE LLC IMMUNOCORE COMMERCIAL LLC and IMMUNOCORE IRELAND LIMITED (as additional Credit Parties), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (

INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Profit / Loss and Other Comprehensive Loss for the Three and Nine Months Ended September 30, 2022 and 2021 2 Unaudited Condensed Consolidated Statements of Financial Position as at September 30, 2022 and December 31, 2021 3 Unaudited Condensed Consolidated Stateme

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EX-99.2 3 brhc10043858ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated interim financial statements and the related notes to those statements included as Exhibit 99.1 t

Calculation of Filing Fee Tables Form F-3 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(4) Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value $0.

5,994,620 American Depositary Shares (Representing 5,994,620 Ordinary Shares)

TABLE OF CONTENTS Filed pursuant to Rule 424(b)(7) Registration No. 333-264105 Prospectus Supplement (To prospectus dated April 4, 2022) 5,994,620 American Depositary Shares (Representing 5,994,620 Ordinary Shares) ? ? The selling shareholders referred to in this prospectus supplement may offer and resell up to 5,994,620 of our American Depositary Shares, or ADSs, pursuant to this prospectus suppl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom

Up to $250,000,000 American Depositary Shares Representing Ordinary Shares

TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-264105 Prospectus Supplement (To prospectus dated April 4, 2022) Up to $250,000,000 American Depositary Shares Representing Ordinary Shares ? ? We have entered into a certain Open Market Sale AgreementSM, or Sales Agreement, with Jefferies LLC, or Jefferies, relating to the sale of American Depositary Shares, or ADSs, each ADS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom

Cautionary Note Regarding Forward Looking Statements

Exhibit 99.1 Cautionary Note Regarding Forward Looking Statements This Exhibit contains ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?may,? ?can?, ?will,? ?believe,? ?expect,? ?plan,? ?anticipate,? ?project? and similar expressions (as well as other words or expressions referencing future events or circumstances) are intende

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom

Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “can”, “will,” “believe,” “expect,” “plan,” “anticipate,” “project” an

Exhibit 99.2 Phase 1 dose escalation of IMC-F106C, the first PRAME ? CD3 ImmTAC bispecific protein in solid tumors September 9, 2022 Forward-Looking Statements This presentation contains ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?may,? ?can?, ?will,? ?believe,? ?expect,? ?plan,? ?anticipate,? ?project? and similar express

Sales Agreement, dated as of September 9, 2022, by and between the Company and Jefferies LLC

EX-1.1 2 brhc10041748ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM September 9, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Immunocore Holdings plc, a public limited company incorporated under the laws of England and Wales with registered number 13119746 (the “Company”), proposes, subject to the terms and conditions stated herein, to issue

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee(3) Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value $0.

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME×CD3 ImmTAC, activates T cells and is well tolerated Dura

Exhibit 99.1 Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME?CD3 ImmTAC, activates T cells and is well tolerated Durable RECIST responses and reduction in circulating tumor DNA (ctDNA) observed across multiple solid tumors Four expansion arms enrolling i

IMCR / Immunocore Holdings plc / Malin Life Sciences Holdings Ltd - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value ?0.002 per share (Title of Class of Securities) 45258D105** (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany, and paid access in France Net KIMMTRAK / tebentafusp revenues of £27.7 million ($33.7 million) in Q2 2022 Transitioned all patients in Ge

Exhibit 99.3 PRESS RELEASE Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK? (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany, and paid access in France Net KIMMTRAK / tebentafusp revenues of ?27.7 million ($33.7 million) in Q2 2022 Transitioned all patients in Germany early access program to commerc

INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Loss for the Three and Six Months Ended June 30, 2022 and 2021 2 Unaudited Condensed Consolidated Statements of Financial Position as at June 30, 2022 and December 31, 2021 3 Unaudited Condensed Consolidated Statements of Changes in Eq

Q2 FINANCIAL RESULTS & BUSINESS UPDATE WEDNESDAY, AUGUST 10, 2022 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,

Exhibit 99.4 Q2 FINANCIAL RESULTS & BUSINESS UPDATE WEDNESDAY, AUGUST 10, 2022 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?may,? ?will,? ?believe,? ?expect,? ?plan,? ?anticipate,? ?project? and similar expressions (as well as other words or expressions referencing future

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated interim financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K, or this Report, sub

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-399

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Ad

Agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k)(1) under the Exchange Act.

EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13D-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.

Shareholders’ Agreement relating to Immunocore Holdings Limited by and among the Series C Investors, the Series B Investors, the Series A Investors and the Qualifying Ordinary Shareholders and Immunocore Holdings Limited, dated January 22, 2021.

EXHIBIT 4 DATED JANUARY 22, 2021 THE SERIES C INVESTORS and THE SERIES B INVESTORS and THE SERIES A INVESTORS and THE QUALIFYING ORDINARY SHAREHOLDERS and IMMUNOCORE HOLDINGS LIMITED SHAREHOLDERS? AGREEMENT relating to Immunocore Holdings Limited Contents Page 1.

Securities Purchase Agreement by and among the Company, Baker Brothers Life Sciences L.P., 667, L.P. and GA IMC, dated July 15, 2022.

EXHIBIT 2 CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN REDACTED BECAUSE SUCH INFORMATION IS NOT MATERIAL AND DISCLOSURE THEREOF WOULD CONSTITUTE AN INVASION OF PERSONAL PRIVACY.

Registration Rights Agreement by and among the Company, 667, L.P., Baker Brothers Life Sciences, L.P., GA IMC, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Venture Fund Limited, Rock Springs Capital Master Fund LP, and Four Pines Master Fund LP, dated July 15, 2022

EXHIBIT 3 CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN REDACTED BECAUSE SUCH INFORMATION IS NOT MATERIAL AND DISCLOSURE THEREOF WOULD CONSTITUTE A INVASION OF PERSONAL PRIVACY.

IMCR / Immunocore Holdings plc / GENERAL ATLANTIC LLC - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value ?0.002 (Title of Class of Securities) 45258D105 (CUSIP Number) Michael Gosk c/o General Atlantic Service Company, L.P. 55 East 52nd Street, 33rd Floor New York, New York 10055 (212) 715-4000 (Name, Add

Immunocore Announces $140 Million Private Placement Financing

Exhibit 99.3 PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq: IMCR) (?Immunocore? or the ?Company?), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a br

IMCR / Immunocore Holdings plc / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No.

Registration Rights Agreement

Exhibit 99.2 Registration Rights Agreement This Registration Rights Agreement (this ?Agreement?) is entered into as of July 15, 2022, by and among Immunocore Holdings plc, a public limited company incorporated in England and Wales with Company number 13119746 (the ?Company?), and the investors listed on the attached Schedule A who are signatories to this Agreement (individually as an ?Investor? an

SECURITIES PURCHASE AGREEMENT

Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is made and entered into as of July 15, 2022 (the ?Execution Date?) by and among Immunocore Holdings plc (registered number 13119746), a public limited company incorporated in England and Wales whose registered office is at 92 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY United Kingdom (the

July 15, 2022

Exhibit 99.2 July 15, 2022 Via Email Immunocore Holdings plc 92 Park Drive Milton Park Abingdon, Oxfordshire United Kingdom OX14 4RY Re: Beneficial Ownership Conversion Limitations Dear Sirs/Madams: Reference is made to the Articles of Association of Immunocore Holdings plc (?Immunocore?) adopted by a special resolution effective on 3 February 2021 (the ?Articles?), which became effective on 9 Feb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2022 Commission File Number: 001-39992

6-K 1 brhc100397556k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2022 Commission File Number: 001-39992

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Addr

Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen Single Ascending Dose portion of Phase 1 study to evaluate safety, antiviral activity, and pharmacokinetics

Exhibit 99.1 PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV? bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen Single Ascending Dose portion of Phase 1 study to evaluate safety, antiviral activity, and pharmacokinetics (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 July 2022) Immunocore Holdings plc (Nasdaq: IMCR) (?I

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor bispecific, targets an envelope antigen Single Ascending Dose portion of

Exhibit 99.1 PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV? trial for chronic Hepatitis B at the EASL International Liver Congress? IMC-I109V, T cell receptor bispecific, targets an envelope antigen Single Ascending Dose portion of Phase 1 study to evaluate safety, antiviral activity, and pharmacokinetics In the initial cohort, HBsAg declines and ALT e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992

6-K 1 brhc100390566k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992

6-K 1 brhc100385946k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire

Immunocore Appoints Siddharth Kaul to its Board of Directors

Exhibit 99.1 Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR) (?Immunocore? or the ?Company?), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of dis

The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the firs

Exhibit 99.1 PRESS RELEASE The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK? (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal mela

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Addr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992

6-K 1 brhc100384656k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire

Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Tebentafusp and anti-PDL1 show 1 year overall survival (OS) of

Exhibit 99.1 PRESS RELEASE Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Tebentafusp and anti-PDL1 show 1 year overall survival (OS) of approximately 75% in heavily pre-treated mCM compared to benchmark of 55% Characterization of safety and efficacy in patien

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma Sanofi will evaluate KIMMTRAK in combination

Exhibit 99.1 Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi?s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK? in patients with metastatic cutaneous melanoma Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers SAR444245, a precisely PEGYlated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992

6-K 1 brhc100384546k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire

Calculation of Filing Fee Tables Form S-8 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value $0.

As filed with the Securities and Exchange Commission on May 17, 2022

As filed with the Securities and Exchange Commission on May 17, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39992

6-K 1 brhc100375986k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire O

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EX-99.2 3 brhc10037394ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated interim financial statements and the related notes to those statements included as Exhibit 99.1 t

INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income for the Three Months Ended March 31, 2022 and 2021 2 Unaudited Condensed Consolidated Statements of Financial Position as at March 31, 2022 and December 31, 2021 3 Unaudited Condensed Consolidated Statements of Changes in Equity

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable or metastatic uveal melanoma Promotional launches and

Exhibit 99.3 PRESS RELEASE Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK? (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable or metastatic uveal melanoma Promotional launches and sales of KIMMTRAK ongoing in U.S., Germany, and France All patients in US early access program successfully transitioned t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39992

6-K 1 brhc100373946k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire O

Calculation of Filing Fee Tables Form F-3 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(4) Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value $0.

3,352,357 American Depositary Shares (Representing 3,352,357 Ordinary Shares)

TABLE OF CONTENTS Filed pursuant to Rule 424(b)(7) Registration No. 333- 264105 Prospectus Supplement (To prospectus dated April 4, 2022) 3,352,357 American Depositary Shares (Representing 3,352,357 Ordinary Shares) ? The selling shareholders referred to in this prospectus supplement may offer and resell up to 3,352,357 of our American Depositary Shares, or ADSs, pursuant to this prospectus supple

Immunocore Holdings plc (incorporated and registered in England and Wales under the Companies Act 2006 with registered number 13119746) Notice of Annual General Meeting 2022 to be held at the offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N 4B

EX-99.1 2 brhc10036395ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant, or other independent professional adviser. If you have recently sold or transferred all of your sh

Annual General Meeting of Shareholders

EX-99.4 5 brhc10036395ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 Annual General Meeting of Shareholders The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on May 6, 2022 for action to be taken. 2022 VOTING INSTRUCTIONS AMERICAN DEPOSITARY SHARES Immunocore Holdings plc (the “Company”) ADS CUSIP No.: 45258D105. RADS CUSIP No.:

EX-99.2

Exhibit 99.2

Time Sensitive

EX-99.3 4 brhc10036395ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Time Sensitive Materials Depositary’s Notice of Annual General Meeting of Shareholders of Immunocore Holdings plc ADSs: American Depositary Shares. ADS CUSIP No.: 45258D105. RADS CUSIP No.: 4525D998. ADS Record Date: April 7, 2022. Meeting Specifics: Annual General Meeting of Shareholders to be held on Thursday, May 12, 2022 at 2 P.M. (Bri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-3999

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Add

European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to treat patients with unresectable or metastatic uveal melanoma KIMMTRA

EX-99.1 2 ny20003567x2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to treat patients with unresectable or metastatic uveal melanoma KIMMTRAK demonstrated statistically and clinically meaningful overall survival (OS)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-3999

6-K 1 ny20003567x26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxford

IMMUNOCORE HOLDINGS PLC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20__ Debt Securities TABLE OF CONTENTS

Exhibit 4.4 IMMUNOCORE HOLDINGS PLC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Sec

IMMUNOCORE HOLDINGS PLC and _____________, As Warrant Agent Form of Ordinary Shares Warrant Agreement Dated As OF __________ Immunocore Holdings plc Form of Ordinary Shares Warrant Agreement

Exhibit 4.6 IMMUNOCORE HOLDINGS PLC and , As Warrant Agent Form of Ordinary Shares Warrant Agreement Dated As OF Immunocore Holdings plc Form of Ordinary Shares Warrant Agreement This Ordinary Shares Warrant Agreement (this ?Agreement?), dated as of [?], between Immunocore Holdings plc, a public limited company incorporated under the laws of England and Wales under company number 13119746 and havi

As filed with the Securities and Exchange Commission on April 4, 2022

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 4, 2022 Registration No.

Calculation of Filing Fee Tables Form F-3 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities

EX-FILING FEES 8 ny20003567x1ex107.htm FILING FEES TABLE Exhibit 107 Calculation of Filing Fee Tables   Form F-3 (Form Type)   Immunocore Holdings plc (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Agg

IMMUNOCORE HOLDINGS PLC and _____________, As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of __________ Immunocore Holdings plc Form of Debt Securities Warrant Agreement

EX-4.7 4 ny20003567x1ex4-7.htm EXHIBIT 4.7 Exhibit 4.7 IMMUNOCORE HOLDINGS PLC and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Immunocore Holdings plc Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Immunocore Holdings plc, a public limited company incorporated under the laws of England and W

IMCR / Immunocore Holdings plc / Cross Nicholas John - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immunocore Holdings PLC (Name of Issuer) Ordinary Shares, nominal value £0.002 (Title of Class of Securities) 45258D105 (CUSIP Number) December 31 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Brian Di Donato, certify that: 1. I have reviewed this annual report on Form 20-F of Immunocore Holdings plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statemen

Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bahija Jallal, certify that: 1. I have reviewed this annual report on Form 20-F of Immunocore Holdings plc (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-3999

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant?s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom (Add

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-255182) on Form S-8 of our report dated March 3, 2022, with respect to the consolidated financial statements of Immunocore Holdings plc. /s/ KPMG LLP London, United Kingdom March 3, 2022

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT IMMUNOCORE TREATS AS PRIVATE OR CONFIDENTIAL.

EX-4.24 5 brhc10034614ex4-24.htm EXHIBIT 4.24 Exhibit 4.24 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT IMMUNOCORE TREATS AS PRIVATE OR CONFIDENTIAL. October 8, 2021 Immunocore Limited 92 Park Drive Milton Park Abingdon Oxon OX14 4RY United Kingdom Attn: Dr.Bahija Jallal, CEO Dear Dr. Ja

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT

Exhibit 4.22 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of January 22, 2021 (the ?First Amendment Date?), by and among OXFORD FINANCE LUXEMBOURG S.? R.L., a Luxembourg private limited liability company (soci?t? ? responsabilit? limit?e) with registered office at 2 route d?Arlon, 8008 Strassen, Grand Duchy

Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F of Immunocore Holdings plc (the ?Company?) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date

SECOND AMENDMENT TO LOAN AND SECUR ITY AGREEMENT

Exhibit 4.23 SECOND AMENDMENT TO LOAN AND SECUR ITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this " Amendment ") is entered into as of September 10, 2021 (the "Second Amendment Date"), by and among OXFORD FINANCE LUXEMBOURG S.? R.L., a Luxembourg private limited liability company (soci?t? ? responsabilit? limit?e) with registered office at 2 route d'Arlon, 8008 Strassen, Gra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC

Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic uveal melanoma; initiated US commercial launch Positive opinion from Eur

Exhibit 99.1 PRESS RELEASE Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK? (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic uveal melanoma; initiated US commercial launch Positive opinion from European Medicines Agency?s Committee for Medicinal Products for Human Use (CHMP); KIMMTRAK regulatory submissions accepted fo

February 8

EX-4.21 2 brhc10034614ex4-21.htm EXHIBIT 4.21 Exhibit 4.21 February 8th 2021 Immunocore Limited 92 Park Drive Milton Park Abingdon Oxon OX14 4RY United Kingdom Attn: Dr. Bahija Jallal, CEO Dear Dr. Jallal: Reference is made to that certain Collaboration and Licence Agreement between Immunocore Limited (“Immunocore”) and GlaxoSmithKline Intellectual Property Development Limited (“GSK”) dated June 2

Thursday, March 3, 2022

Exhibit 99.2 Thursday, March 3, 2022 Dear Fellow Shareholders, Reflecting on what has been a transformative time for Immunocore, I am extremely pleased with all we have been able to achieve over the last three years, culminating in the FDA approval of our lead product KIMMTRAK? (tebentafusp-tebn) for the treatment of metastatic uveal melanoma (mUM). This was a significant milestone for patients, a

Joint Filing Agreement, dated February 18, 2022, entered into by Ian Michael Laing and Caroline Elizabeth Laing.

EXHIBIT 2 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary Shares, nominal value ?0.

IMCR / Immunocore Holdings plc / Laing Ian Michael - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value £0.002 per share (Title of Class of Securities) 45258D105** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

Identification of Members of the Group

EXHIBIT 1 IDENTIFICATION OF MEMBERS OF THE GROUP The members of the group filing the statement on Schedule 13G with respect to the Ordinary Shares, nominal value ?0.002 per share, of Immunocore Holdings plc, dated as of February 18, 2022, of which this Exhibit 1 is a part, are as follows: Ian Michael Laing Caroline Elizabeth Laing

IMCR / Immunocore Holdings plc / Rock Springs Capital Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

Power of Attorney

EX-99.2 3 d299755dex992.htm EX-99.2 Exhibit 99.2 Power of Attorney The undersigned, ELI LILLY S.A., a Swiss société anonyme (the “Company”), does hereby make, constitute and appoint each of Anat Hakim, Christopher Anderson and Jonathan Groff acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Compan

Joint Filing Agreement

EX-99.1 2 d299755dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement IN ACCORDANCE WITH Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares, nominal value £0.002 per share, of Immunocore Holdings plc, an Eng

IMCR / Immunocore Holdings plc / ELI LILLY & Co - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value ?0.002 per share (Title of Class of Securities) 54258D105** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

Power of Attorney

Exhibit 99.3 Power of Attorney The undersigned, ELI LILLY AND COMPANY, a corporation duly organized under the laws of the State of Indiana, United States (the ?Company?), does hereby make, constitute and appoint each of Anat Hakim, Christopher Anderson and Jonathan Groff acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on

IMCR / Immunocore Holdings plc / Malin Life Sciences Holdings Ltd - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immunocore Holdings plc (Name of Issuer) Ordinary Shares, nominal value ?0.002 per share (Title of Class of Securities) 45258D105** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39

6-K 1 brhc100331226k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39992 Immunocore Holdings plc (Translation of registrant’s name into English) 92 Park Drive Milton Park Abingdon, Oxfordshi

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only FDA approved therapy for the treatment of unresectable or metastatic uveal melanoma (mUM)

Exhibit 99.1 PRESS RELEASE Immunocore announces FDA approval of KIMMTRAK? (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only FDA approved therapy for the treatment of unresectable or metastatic uveal melanoma (mUM) KIMMTRAK is the first T cell receptor (TCR) therapeutic to receive regulatory approval KIMMTRAK demonstrated statistically